がん治療薬市場：投与経路、治療タイプ、種類、エンドユーザー別-2025-2030年の世界予測

がん治療薬市場は、2023年に1,445億米ドルと評価され、2024年には1,577億6,000万米ドルに達すると予測され、CAGR 9.57％で成長し、2030年には2,740億5,000万米ドルに達すると予測されています。

がん治療薬市場には、さまざまな形態のがんの治療を目的とした多様な治療ソリューションが含まれます。この市場には、化学療法、免疫療法、標的療法、ホルモン療法、その他の革新的治療が含まれます。がん治療薬の必要性は、世界のがん罹患率の上昇、医療技術の進歩、早期発見と治療オプションに対する意識の高まりによって裏付けられています。これらの医薬品は、病院、診療所、がん専門治療センターなど、複数のエンドユーザーに応用されています。市場成長の主な影響要因としては、製薬企業による研究開発投資の増加、精密医療における著しい進歩、新規がん治療薬の承認率の上昇などが挙げられます。老年人口の急増とライフスタイルの変化は、効果的ながん治療への需要をさらに促進しています。潜在的な治療機会は、個別化医療の採用の高まりと、費用対効果の高い治療選択肢を提供するバイオシミラーの受け入れ拡大にあります。企業は、バイオシミラーの開発や個々の患者のプロファイルに合わせた精密医療の開発に注力することで、こうした機会を活用することができます。しかし、新興国市場は、医薬品開発にかかる高いコスト、厳格な規制要件、がんの病態生理の複雑さといった限界にも直面しており、これが技術革新や市場参入の妨げとなっています。さらに、がん治療に伴う副作用は、広く受け入れられるための課題となっています。革新と調査は、ドラッグデリバリーシステムの強化、併用療法の探求、早期診断と個別化治療計画のためのAIの活用に軸足を置き、それによって患者の転帰を改善しながら企業に成長の道を提供することができます。がん治療薬市場は競争が激化しており、頻繁な技術進歩や戦略的提携が特徴となっています。成功する企業は、事業の俊敏性を維持し、新たな技術を活用し、効果的な新しい治療法をタイムリーに市場に投入するために規制状況を効果的にナビゲートする企業です。

市場力学：急速に進化するがん治療薬市場の主要市場インサイトを公開

がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん疾患の増加と認知度の向上
  • 政府および医療機関のがん治療に対する支援策
• 市場抑制要因
  • 高い研究開発費と抗がん剤に関連する製品回収問題
• 市場機会
  • 個別化がん治療につながるゲノム・分子研究の進展
  • ジェネリック医薬品開発への投資の増加
• 市場の課題
  • がん治療薬に関連する厳しい規制要件

ポーターの5つの力：がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん治療薬市場における競合情勢の把握

がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん治療薬市場における成功への道筋を描く

がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん疾患の数と認知度の増加
    • 政府と保健機関によるがん治療支援の取り組み
  • 抑制要因
    • がん治療薬に関連する高額な研究開発費と製品回収問題
  • 機会
    • ゲノムと分子の調査の進歩ががんの個別治療につながる
    • ジェネリック医薬品開発への投資増加
  • 課題
    • がん治療薬に関連する厳格な規制要件
• 市場セグメンテーション分析
  • 治療の種類：長期寛解と副作用の減少により免疫療法が好まれる傾向が高まっている
  • エンドユーザー：在宅ケアにおけるパーソナライズ医療プランの好感度が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん治療薬市場：投与経路別

• 静脈内
• オーラル
• 話題

第7章 がん治療薬市場治療の種類別

• 化学療法
• 併用療法
• ホルモン療法
• 免疫療法
• 放射線治療
• 標的療法

第8章 がん治療薬市場：タイプ別

• 膀胱がん
• 乳がん
• 子宮頸がん
• 大腸がん
• 食道がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 前立腺がん
• 胃がん

第9章 がん治療薬市場：エンドユーザー別

• クリニック
• ホームケア
• 病院

第10章 南北アメリカのがん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ランタン・ファーマシューティカルズとOHSUが協力し、AIを活用した先進的ながん治療法を開発
  • 小野薬品工業、腫瘍学ポートフォリオ強化のためデシフェラ・ファーマシューティカルズを24億米ドルで買収
  • ザイダス・ライフサイエンス、新薬イビラの発売でインドにおけるがん治療の選択肢を拡大
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen MA Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• Eli Lilly and Company
• F. Hofmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Incyte Corporation
• Ipsen Pharma
• Johnson & Johnson Services, Inc.
• Mallinckrodt PLC
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi Group
• Sumitomo Pharma Co., Ltd.
• Sun Pharmaceuticals Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. CHINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. INDIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. INDIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. INDIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. ITALY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. ITALY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. ITALY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. ITALY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. POLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. POLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 159. POLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. POLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. QATAR CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. QATAR CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 163. QATAR CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. QATAR CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 202. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Drugs Market was valued at USD 144.50 billion in 2023, expected to reach USD 157.76 billion in 2024, and is projected to grow at a CAGR of 9.57%, to USD 274.05 billion by 2030.

The cancer drugs market encompasses a diverse range of therapeutic solutions aimed at treating various forms of cancer. This market includes chemotherapy, immunotherapy, targeted therapy, hormone therapy, and other innovative treatments. The necessity of cancer drugs is underscored by the rising prevalence of cancer globally, advancing medical technology, and increasing awareness about early detection and treatment options. These drugs find application across multiple end-users such as hospitals, clinics, and specialized cancer treatment centers. Key influencing factors for market growth include heightened investment in R&D by pharmaceutical companies, significant advancements in precision medicine, and the increasing approval rates of new cancer drugs. The surge in geriatric population and lifestyle changes further expedite the demand for effective cancer treatments. Potential opportunities lie in the rising adoption of personalized medicine and the growing acceptance of biosimilars, which provide cost-effective treatment alternatives. Companies can leverage these opportunities by intensifying their focus on developing biosimilars and precision medicine tailored to individual patient profiles. However, the market also faces limitations such as high costs of drug development, rigorous regulatory requirements, and the complex nature of cancer pathophysiology, which can hamper innovation and market entry. Additionally, side effects associated with cancer treatments pose challenges to widespread acceptance. Innovation and research could pivot towards enhancing drug delivery systems, exploring combination therapies, and leveraging AI for early diagnosis and personalized treatment plans, thereby offering businesses growth avenues while improving patient outcomes. The cancer drugs market is increasingly competitive, characterized by frequent technological advancements and strategic collaborations. Companies that will succeed are those that maintain agility in their operations, capitalize on emerging technologies, and navigate regulatory landscapes effectively to bring new, effective treatments to market in a timely manner.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Drugs Market

The Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number and awareness of cancer diseases
  • Governments and health organizations' supportive initiatives for cancer treatment
• Market Restraints
  • High R&D cost and product recall issues associated with cancer drug
• Market Opportunities
  • Advancements in genomic and molecular research leading to personalized cancer treatments
  • Increasing investment in generic medicine development
• Market Challenges
  • Stringent regulatory requirements associated with cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Drugs Market

A detailed market share analysis in the Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Drugs Market

A strategic analysis of the Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen MA Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hofmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Ipsen Pharma, Johnson & Johnson Services, Inc., Mallinckrodt PLC, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Group, Sumitomo Pharma Co., Ltd., Sun Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
• Based on Type of Therapy, market is studied across Chemotherapy, Combination Therapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
• Based on Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
• Based on End-User, market is studied across Clinics, Homecare, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number and awareness of cancer diseases
    • 5.1.1.2. Governments and health organizations' supportive initiatives for cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D cost and product recall issues associated with cancer drug
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in genomic and molecular research leading to personalized cancer treatments
    • 5.1.3.2. Increasing investment in generic medicine development
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements associated with cancer drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type of therapy : Increasing preference for immunotherapy due to its long-term remission and reduced side effects
  • 5.2.2. End-user : Rising preference for personalized medicine plans in homecare
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Drugs Market, by Route of Administration

• 6.1. Introduction
• 6.2. Intravenous
• 6.3. Oral
• 6.4. Topical

7. Cancer Drugs Market, by Type of Therapy

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Combination Therapy
• 7.4. Hormonal Therapy
• 7.5. Immunotherapy
• 7.6. Radiation Therapy
• 7.7. Targeted Therapy

8. Cancer Drugs Market, by Type

• 8.1. Introduction
• 8.2. Bladder Cancer
• 8.3. Breast Cancer
• 8.4. Cervical Cancer
• 8.5. Colorectal Cancer
• 8.6. Esophagus Cancer
• 8.7. Kidney Cancer
• 8.8. Liver Cancer
• 8.9. Lung Cancer
• 8.10. Prostate Cancer
• 8.11. Stomach Cancer

9. Cancer Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Homecare
• 9.4. Hospitals

10. Americas Cancer Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Lantern Pharmaceuticals and OHSU Join Forces to Develop Advanced AI-Driven Cancer Treatments
  • 13.3.2. Ono Pharmaceutical Acquires Deciphera Pharmaceuticals in USD 2.4 Billion Deal to Bolster Oncology Portfolio
  • 13.3.3. Zydus Lifesciences Expands Cancer Treatment Options in India with Launch of New Drug Ibyra
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Biogen MA Inc.
• 7. Boehringer Ingelheim GmbH
• 8. Bristol-Myers Squibb Company
• 9. Cipla Limited
• 10. Eli Lilly and Company
• 11. F. Hofmann-La Roche Ltd.
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline PLC
• 14. Incyte Corporation
• 15. Ipsen Pharma
• 16. Johnson & Johnson Services, Inc.
• 17. Mallinckrodt PLC
• 18. Merck KGaA
• 19. Novartis AG
• 20. Pfizer, Inc.
• 21. Regeneron Pharmaceuticals, Inc.
• 22. Sanofi Group
• 23. Sumitomo Pharma Co., Ltd.
• 24. Sun Pharmaceuticals Limited
• 25. Takeda Pharmaceutical Company Limited
• 26. Teva Pharmaceutical Industries Ltd.